Open Access Repository

Effect of atorvastatin on cognitive function in patients from the lipid lowering and onset of renal disease (LORD) trial

Downloads

Downloads per month over past year

Summers, MJ and Oliver, KR and Coombes, JS and Fassett, RG (2007) Effect of atorvastatin on cognitive function in patients from the lipid lowering and onset of renal disease (LORD) trial. Pharmacotherapy: the journal of human pharmacology and drug therapy, 27 (2). pp. 183-190. ISSN 0277-0008

[img] PDF
4455.pdf | Request a copy
Full text restricted
Available under University of Tasmania Standard License.

Abstract

Study Objective. To examine the effect of atorvastatin on cognitive function
by testing two hypotheses: that atorvastatin 10 mg/day would impair
cognitive function, and that other biochemical and demographic measures
would better predict cognitive performance than atorvastatin alone.
Design. Randomized, double-blind, placebo-controlled study.
Setting. Two primary acute care settings in the north and northwest of
Tasmania, Australia.
Patients. Fifty-seven patients from the Lipid Lowering and Onset of Renal
Disease (LORD) trial.
Intervention. Participants were randomly assigned to receive either
atorvastatin 10 mg/day or matching placebo. Cognitive testing was
performed in two sessions occurring 12 weeks apart and involved three
repeated measures of attention and concentration.
Measurements and Main Results. Performance was measured using three
standard neuropsychological tests: Digit Symbol Coding subtest, Trail
Making Test, and Stroop Color-Word Reading Test. Patients received
atorvastatin for a mean of 72.93 weeks and placebo for a mean of 68.85
weeks. Repeated-measures multivariate analysis of variance failed to
identify any significant differences between the two groups on any of the
three cognitive measures. Multiple regression analyses identified no single
factor or combination of plasma cholesterol levels, renal function, liver
function, or age that predicted cognitive performance in either the
atorvastatin or placebo group on the three measures at either testing
session.
Conclusion. Atorvastatin 10 mg/day did not produce decrements to cognitive
performance. In addition, biochemical and demographic measures and the
receipt of atorvastatin versus placebo did not individually or in
combination predict cognitive performance on measures of attention and
concentration.

Item Type: Article
Keywords: attention, concentration, atorvastatin, statins, cognition, renal disease.
Journal or Publication Title: Pharmacotherapy: the journal of human pharmacology and drug therapy
Publisher: Richard Scheife
Page Range: pp. 183-190
ISSN: 0277-0008
Identification Number - DOI: 10.1592/phco.27.2.183
Date Deposited: 07 Apr 2008 14:40
Last Modified: 18 Nov 2014 03:35
Item Statistics: View statistics for this item

Actions (login required)

Item Control Page Item Control Page
TOP